Physician profile
Debra Stock
NPI 1376623215
$4,802.14
in general payments reported to CMS, 2019-2025
16 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.93 · 2022: $498 · 2023: $1,167 · 2024: $1,706 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,098 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,098.30 |
| Education | $111.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,403.76 | 2021-2025 | |
| Lilly USA, LLC | $990.52 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $689.11 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $444.43 | 2023-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $319.22 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $180.18 | 2022-2025 | |
| Genzyme Corporation | $177.56 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $117.40 | 2023-2025 | Ilumya |
| Galderma Laboratories, L.P. | $112.46 | 2025 | Nemluvio |
| Leo Pharma INC. | $112.45 | 2023-2025 | Adbry |
| Pfizer INC. | $86.06 | 2023-2024 | |
| Amgen INC. | $41.31 | 2022-2025 | Otezla |
| Arcutis Biotherapeutics, INC. | $39.19 | 2025 | Zoryve |
| Strata Skin Sciences, INC. | $38.39 | 2024 | Xtrac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.52 | 2023 | Spevigo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.58 | 2024 | Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Stock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.